This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Google, Depomed: After-Hours Trading

NEW YORK (TheStreet) -- Shares of Google (GOOG) jumped in late trades on Thursday after the Internet search giant trounced Wall Street's earnings expectations for its third-quarter results.

"We had a great quarter," said Larry Page, CEO of Google, in a statement. "Revenue was up 33% year on year and our quarterly revenue was just short of $10 billion. Google+ is now open to everyone and we just passed the 40 million user mark. People are flocking into Google+ at an incredible rate and we are just getting started!"

The company reported non-GAAP earnings of $3.18 billion, or $9.72 a share, for the three months ended in September. Revenue totaled $9.72 billion. Excluding traffic acquisition costs of $2.21 billion, revenue came in at $7.51 billion. The average estimate of analysts polled by Thomson Reuters was for earnings of $8.74 a share for the quarter on revenue of $7.22 billion.

The stock was last quoted at $594.50, up 6.4%, on volume of 1.31 million, according to Nasdaq.com. Based on a regular session close at $558.99, the shares were down roughly 7.7% so far in 2011, although they've seen a healthy bounce since plumbing a 52-week low of $473.02 on June 24.

Google reported increases in both paid clicks and cost-per-click on year-over-year basis but did see a decline of 5% in cost-per-click on a sequential basis.

Depomed

The big loser after Thursday's closing bell was Depomed (DEPO), which disappointed with the clinical results of a late-stage trial of Serada, its proposed drug to treat menopausal hot flashes.

The shares plunged 27% to $4.60 in extended trading with volume running above 405,000, according to Nasdaq.com.

Depomed said efficacy data from the phase III trial of Serada was "positive and statistically significant for three of the four pre-specified primary endpoints of frequency and severity at four and 12 weeks" and that data for key secondary endpoints at 24 weeks didn't achieve "statistical significance."

The company said the safety data found the tablets were well-tolerated and that it plans to discuss "possible pathways" for a new drug application with the Food and Drug Administration.

Stock quotes in this article: GOOG, DEPO, NCMI 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs